NCT05091567 2026-03-10IMforteHoffmann-La RochePhase 3 Active not recruiting660 enrolled 23 charts 1 FDA
NCT03735121 2025-12-05A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung CancerHoffmann-La RochePhase 3 Completed438 enrolled 40 charts 1 FDA
NCT02409342 2023-03-15A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]Hoffmann-La RochePhase 3 Completed572 enrolled 32 charts 2 FDA